隶属于 wuxi hequan pharmaceutical technology co., ltd.
相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2002
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Discovery teams are moving potency down from its dominant position, evaluating binding kinetics, target engagement duration, ADME and DMPK properties earlier in optimization programs. - Simple biochemical and cellular assays miss cell permeability, target abundance, protein turnover and toxicity effects that determine whether a mechanism holds up in realistic biological systems. - Newer modalities such as targeted protein degraders and antibody-drug conjugate payloads add delivery and intracellular considerations that demand evidence from more physiologically relevant models. - Direct-to-Biology workflows and closer chemistry-biology integration aim to deliver findings while they can still shape the next design cycle rather than several cycles later.
- Manufacturing accounts for roughly 80% of a pharmaceutical company's environmental footprint, making the factory floor the critical intervention point for meaningful change. - Eight leading APAC CDMOs are integrating renewable electricity, water reuse, waste recovery, green chemistry and continuous manufacturing into core production strategy rather than isolated initiatives. - The global sustainable drug manufacturing market is projected to grow from USD 105.8 billion in 2026 to USD 248.2 billion by 2036 at an 8.9% CAGR. - Scope 3 emissions, supplier engagement and internal carbon pricing are emerging as the next frontier, with WuXi AppTec reporting 82.14% of emissions from Scope 3.
- The global women's clinical trials and CRO market is projected to grow from $9.9 billion in 2026 to $22.3 billion by 2036, at a CAGR of 8.5%. - Growth is driven by rising prevalence of women-predominant conditions, regulatory requirements for sex-specific safety evaluation, and precision medicine adoption. - Decentralized trial models are accelerating enrollment; Lindus Health's hybrid trials leveraged over 30 million EHRs to double enrollment speed versus traditional approaches. - U.S.-China tariff friction is disrupting biospecimen flows and central lab operations, prompting sponsors to shift recruitment toward CRO networks in India, Southeast Asia, and Europe.
- The US Department of Defense added WuXi AppTec to its Section 1260H list of "Chinese military companies," triggering provisions under the Biosecure Act. - WuXi AppTec, which generates three-quarters of its revenue from the US, has denied any association with the Chinese government and plans to appeal the designation. - Under the Biosecure Act, US companies with preexisting contracts have a 5-year transition period starting in 2028, but analysts warn supply chain disruptions could begin much earlier. - Analysts suggest European and North American competitors such as Bachem, PolyPeptide Group, Charles River Laboratories, and Evotec could benefit from the shift away from WuXi AppTec.
- Evotec SE operates as a drug discovery partner leveraging proprietary platforms in small molecules, biologics, and AI-driven chemistry to accelerate candidates for pharmaceutical clients including Bayer and Bristol Myers Squibb. - The company's industrialized approach to R&D treats discovery like manufacturing, using high-throughput screening and modular technologies to achieve hit rates above industry averages while reducing timelines. - Evotec's dual-segment structure balances contract research revenue through EVT Execute with upside potential from co-developed assets via EVT Innovate, providing exposure to multiple pipelines while reducing clinical failure risks. - Strategic expansion into the U.S. market through acquisitions and partnerships positions the company to capture share of global pharma R&D budgets exceeding $200 billion annually.
